Related references
Note: Only part of the references are listed.Successful in-flight activation of natural killer cells during long-distance shipping
Scott A. Koepsell et al.
TRANSFUSION (2013)
Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation
Lorenzo Moretta et al.
BLOOD (2011)
Natural Killer Cell Killing of Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia Blasts by Killer Cell Immunoglobulin-Like Receptor-Negative Natural Killer Cells after NKG2A and LIR-1 Blockade
Robert Godal et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Natural Killer Cell-Enriched Donor Lymphocyte Infusions from A 3-6/6 HLA Matched Family Member following Nonmyeloablative Allogeneic Stem Cell Transplantation
David A. Rizzieri et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia
Sarah Cooley et al.
BLOOD (2010)
Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies
William Reed et al.
TRANSFUSION (2009)
Transfusion-associated graft-versus-host disease: a perspective from a cell therapy laboratory
D. Hummon et al.
TRANSFUSION (2009)
Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells
Laurent Boissel et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
S. Arai et al.
CYTOTHERAPY (2008)
Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis
Christine E. Eyler et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Up on the tightrope: natural killer cell activation and inhibition
Lewis L. Lanier
NATURE IMMUNOLOGY (2008)
Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines
Rosa Mendez et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Steven A. Rosenberg et al.
NATURE REVIEWS CANCER (2008)
Donor natural killer cell allorecognition of missing self in haploidentical hernatopoietic transplantation for acute myeloid leukemia: challenging its predictive value
Loredana Ruggeri et al.
BLOOD (2007)
Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT
Jeffery S. Miller et al.
BLOOD (2007)
Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors
Andreas Lundqvist et al.
BLOOD (2007)
Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience
D. H. McKenna et al.
TRANSFUSION (2007)
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: A report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry
Sherif S. Farag et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
CD4+-CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer
MJ Smyth et al.
JOURNAL OF IMMUNOLOGY (2006)
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
JS Miller et al.
BLOOD (2005)
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
ME Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
CA Klebanoff et al.
TRENDS IN IMMUNOLOGY (2005)
Graft-versus-leukemia reactions in allogeneic chimeras
HJ Kolb et al.
BLOOD (2004)
The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules:: implications for tumor immune escape
I Algarra et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Effective immunotherapy against cancer - A question of overcoming immune suppression and immune escape?
KJ Malmberg
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Share Paper
